CCL24, C-C motif chemokine ligand 24, 6369

N. diseases: 67; N. variants: 3
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0032285
Disease: Pneumonia
Pneumonia 		0.340 Biomarker disease BEFREE We further investigated the efficacy of an anti-CCL24 monoclonal antibody (mAb), CM-101, in inhibiting cell activation as well as dermal and pulmonary inflammation and fibrosis in experimental animal models. 31129606 2019
CUI: C3714636
Disease: Pneumonitis
Pneumonitis 		0.340 Biomarker disease BEFREE We further investigated the efficacy of an anti-CCL24 monoclonal antibody (mAb), CM-101, in inhibiting cell activation as well as dermal and pulmonary inflammation and fibrosis in experimental animal models. 31129606 2019
CUI: C0032285
Disease: Pneumonia
Pneumonia 		0.340 Biomarker disease BEFREE TPL-2 inhibited Ccl24 expression in lung DCs, and blockade of Ccl24 prevented the exaggerated airway eosinophilia and lung inflammation in mice given HDM-pulsed Map3k8<sup>-/-</sup> DCs. 27484038 2017
CUI: C3714636
Disease: Pneumonitis
Pneumonitis 		0.340 Biomarker disease BEFREE TPL-2 inhibited Ccl24 expression in lung DCs, and blockade of Ccl24 prevented the exaggerated airway eosinophilia and lung inflammation in mice given HDM-pulsed Map3k8<sup>-/-</sup> DCs. 27484038 2017
CUI: C0032285
Disease: Pneumonia
Pneumonia 		0.340 Biomarker disease BEFREE A transgenic mouse model of chronic T helper (Th) 2-driven inflammation expressing IL-5 from T cells and human eotaxin-2 locally in the lung (I5/hE2) was used to define potential in vivo relationships among eosinophils, leukotrienes, and chronic Th2-polarized pulmonary inflammation. 23859654 2013
CUI: C3714636
Disease: Pneumonitis
Pneumonitis 		0.340 Biomarker disease BEFREE A transgenic mouse model of chronic T helper (Th) 2-driven inflammation expressing IL-5 from T cells and human eotaxin-2 locally in the lung (I5/hE2) was used to define potential in vivo relationships among eosinophils, leukotrienes, and chronic Th2-polarized pulmonary inflammation. 23859654 2013
CUI: C0032285
Disease: Pneumonia
Pneumonia 		0.340 Biomarker disease CTD_human Expansion of CD4(+) CD25(+) and CD25(-) T-Bet, GATA-3, Foxp3 and RORγt cells in allergic inflammation, local lung distribution and chemokine gene expression. 21625544 2011
CUI: C3714636
Disease: Pneumonitis
Pneumonitis 		0.340 Biomarker disease CTD_human Expansion of CD4(+) CD25(+) and CD25(-) T-Bet, GATA-3, Foxp3 and RORγt cells in allergic inflammation, local lung distribution and chemokine gene expression. 21625544 2011
CUI: C0032285
Disease: Pneumonia
Pneumonia 		0.340 Biomarker disease BEFREE Identification of a cooperative mechanism involving interleukin-13 and eotaxin-2 in experimental allergic lung inflammation. 15647285 2005
CUI: C3714636
Disease: Pneumonitis
Pneumonitis 		0.340 Biomarker disease BEFREE Identification of a cooperative mechanism involving interleukin-13 and eotaxin-2 in experimental allergic lung inflammation. 15647285 2005
CUI: C1269683
Disease: Major Depressive Disorder
Major Depressive Disorder 		0.310 Biomarker disease PSYGENET The two most robust and reliable biomarkers identified across both the discovery and validation cohort were Chemokine (C-C motif) ligand 24 (CCL24) which was consistently transcribed higher amongst MDD patients relative to controls and BPD patients, and C-C chemokine receptor type 6 (CCR6) which was consistently more lowly transcribed amongst MDD patients relative to controls. 24618828 2014
CUI: C1269683
Disease: Major Depressive Disorder
Major Depressive Disorder 		0.310 Biomarker disease BEFREE The two most robust and reliable biomarkers identified across both the discovery and validation cohort were Chemokine (C-C motif) ligand 24 (CCL24) which was consistently transcribed higher amongst MDD patients relative to controls and BPD patients, and C-C chemokine receptor type 6 (CCR6) which was consistently more lowly transcribed amongst MDD patients relative to controls. 24618828 2014
CUI: C0041696
Disease: Unipolar Depression
Unipolar Depression 		0.300 Biomarker disease PSYGENET Putative transcriptomic biomarkers in the inflammatory cytokine pathway differentiate major depressive disorder patients from control subjects and bipolar disorder patients. 24618828 2014
CUI: C0020517
Disease: Hypersensitivity
Hypersensitivity 		0.300 Biomarker group CTD_human Expansion of CD4(+) CD25(+) and CD25(-) T-Bet, GATA-3, Foxp3 and RORγt cells in allergic inflammation, local lung distribution and chemokine gene expression. 21625544 2011
CUI: C0032300
Disease: Lobar Pneumonia
Lobar Pneumonia 		0.300 Biomarker disease CTD_human Expansion of CD4(+) CD25(+) and CD25(-) T-Bet, GATA-3, Foxp3 and RORγt cells in allergic inflammation, local lung distribution and chemokine gene expression. 21625544 2011
CUI: C0887898
Disease: Experimental Lung Inflammation
Experimental Lung Inflammation 		0.300 Biomarker disease CTD_human Expansion of CD4(+) CD25(+) and CD25(-) T-Bet, GATA-3, Foxp3 and RORγt cells in allergic inflammation, local lung distribution and chemokine gene expression. 21625544 2011
CUI: C1527304
Disease: Allergic Reaction
Allergic Reaction 		0.300 Biomarker phenotype CTD_human Expansion of CD4(+) CD25(+) and CD25(-) T-Bet, GATA-3, Foxp3 and RORγt cells in allergic inflammation, local lung distribution and chemokine gene expression. 21625544 2011
CUI: C0011615
Disease: Dermatitis, Atopic
Dermatitis, Atopic 		0.300 Biomarker disease CTD_human Peroxisome proliferator-activated receptor alpha regulates skin inflammation and humoral response in atopic dermatitis. 18249437 2008
CUI: C0086196
Disease: Eczema, Infantile
Eczema, Infantile 		0.300 Biomarker disease CTD_human Peroxisome proliferator-activated receptor alpha regulates skin inflammation and humoral response in atopic dermatitis. 18249437 2008
CUI: C0013182
Disease: Drug Allergy
Drug Allergy 		0.300 Biomarker group CTD_human RANTES, eotaxin and eotaxin-2 expression and production in patients with aspirin triad. 14616128 2003
CUI: C0004096
Disease: Asthma
Asthma 		0.100 AlteredExpression disease BEFREE Eosinophil chemokines eotaxin-1 and eotaxin-2 were significantly upregulated (false discovery rate [FDR] < 0.05) by approximately 2.1- and 1.4-fold in the asthma study and by 2.3- and 1.7-fold in the COPD study following benralizumab treatment. 30658649 2019
CUI: C0004096
Disease: Asthma
Asthma 		0.100 AlteredExpression disease BEFREE Among elderly asthmatics, subjects with severe asthma had lower FEV1 (% predicted) value, but showed significantly higher serum levels of eotaxin-2 and TGF-β1, than those with non-severe asthma (<i>P</i> < 0.05 for each). 30479079 2019
CUI: C0014457
Disease: Eosinophilia
Eosinophilia 		0.100 AlteredExpression disease BEFREE The expression level of HK-1 correlated with CCL24 expression and tissue eosinophilia in eosinophilic nasal polyps. 31545881 2019
CUI: C0014457
Disease: Eosinophilia
Eosinophilia 		0.100 Biomarker disease BEFREE Before and after treatment, the eosinophilic biomarkers in nasal lavage were analyzed: nasal eosinophilia (number of eosinophils per high power field), eotaxin-1 and eotaxin-2. 30478909 2019
CUI: C1306759
Disease: Eosinophilic disorder
Eosinophilic disorder 		0.100 AlteredExpression group BEFREE The expression level of HK-1 correlated with CCL24 expression and tissue eosinophilia in eosinophilic nasal polyps. 31545881 2019